Ascend Wellness Holdings, Inc.
Ascend Wellness Holdings, Inc. (AAWH) Financial Performance & Income Statement Overview
Explore the financials of Ascend Wellness Holdings, Inc. (AAWH), including yearly and quarterly data on income, cash flow, and balance sheets.
Ascend Wellness Holdings, Inc. (AAWH) Income Statement & Financial Overview
Explore comprehensive income reports for Ascend Wellness Holdings, Inc. AAWH, broken down by year and quarter.
Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
---|---|---|---|---|
Revenue | $128.00M | $136.006M | $141.65M | $141.54M |
Cost of Revenue | $88.44M | $89.14M | $97.92M | $99.96M |
Gross Profit | $39.56M | $46.87M | $43.73M | $41.57M |
Gross Profit Ratio | $0.31 | $0.34 | $0.31 | $0.29 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $37.08M | $31.82M | $46.15M | $34.52M |
Operating Expenses | $37.08M | $40.77M | $46.15M | $43.09M |
Total Costs & Expenses | $125.51M | $138.62M | $144.06M | $143.06M |
Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
Interest Expense | -$11.19M | $11.71M | $11.006M | $8.54M |
Depreciation & Amortization | $0.00 | $17.98M | $17.11M | $16.33M |
EBITDA | $2.49M | $23.69M | $9.63M | $15.19M |
EBITDA Ratio | $0.02 | $0.17 | $0.07 | $0.11 |
Operating Income | $2.49M | $6.10M | -$2.42M | -$1.52M |
Operating Income Ratio | $0.02 | $0.04 | -$0.02 | -$0.01 |
Other Income/Expenses (Net) | -$10.71M | -$12.10M | -$16.07M | -$8.16M |
Income Before Tax | -$8.23M | -$6.002M | -$18.49M | -$9.68M |
Income Before Tax Ratio | -$0.06 | -$0.04 | -$0.13 | -$0.07 |
Income Tax Expense | -$11.03M | $10.79M | $9.77M | $12.11M |
Net Income | -$19.26M | -$16.79M | -$28.26M | -$21.78M |
Net Income Ratio | -$0.15 | -$0.12 | -$0.20 | -$0.15 |
EPS | -$0.09 | -$0.08 | -$0.13 | -$0.10 |
Diluted EPS | -$0.09 | -$0.08 | -$0.13 | -$0.10 |
Weighted Avg Shares Outstanding | $205.00M | $212.43M | $214.29M | $213.16M |
Weighted Avg Shares Outstanding (Diluted) | $205.00M | $212.43M | $214.29M | $213.16M |
Over the last four quarters, Ascend Wellness Holdings, Inc. achieved steady financial progress, growing revenue from $141.54M in Q2 2024 to $128.00M in Q1 2025. Gross profit stayed firm with margins at 31% in Q1 2025 versus 29% in Q2 2024. Operating income totaled $2.49M in Q1 2025, maintaining a 2% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $2.49M. Net income dropped to -$19.26M, with EPS at -$0.09. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan